Coronavirus disease 2019 (COVID-19): current status and future perspectives

ABSTRACT Coronavirus disease 2019 (COVID-19) originated in the city of Wuhan, Hubei Province, Central China, and has spread quickly to 72 countries to date. COVID-19 is caused by a novel coronavirus, named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [previously provisionally known as 2019 novel coronavirus (2019-nCoV)]. At present, the newly identified SARS-CoV-2 has caused a large number of deaths with tens of thousands of confirmed cases worldwide, posing a serious threat to public health. However, there are no clinically approved vaccines or specific therapeutic drugs available for COVID-19. Intensive research on the newly emerged SARS-CoV-2 is urgently needed to elucidate the pathogenic mechanisms and epidemiological characteristics and to identify potential drug targets, which will contribute to the development of effective prevention and treatment strategies. Hence, this review will focus on recent progress regarding the structure of SARS-CoV-2 and the characteristics of COVID-19, such as the aetiology, pathogenesis and epidemiological characteristics.

[1]  Jue Fan,et al.  Specific ACE2 Expression in Cholangiocytes May Cause Liver Damage After 2019-nCoV Infection , 2020, bioRxiv.

[2]  Roberto Cauda,et al.  New insights into the antiviral effects of chloroquine , 2006, The Lancet Infectious Diseases.

[3]  Kai Zhao,et al.  A pneumonia outbreak associated with a new coronavirus of probable bat origin , 2020, Nature.

[4]  Chen Wang,et al.  The Involvement of Natural Killer Cells in the Pathogenesis of Severe Acute Respiratory Syndrome , 2004, American journal of clinical pathology.

[5]  Yan Zhao,et al.  Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. , 2020, JAMA.

[6]  R. Eggo,et al.  Effectiveness of airport screening at detecting travellers infected with novel coronavirus (2019-nCoV) , 2020, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[7]  G. Beall,et al.  Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. , 2002, The New England journal of medicine.

[8]  Arthur S Slutsky,et al.  Lung Repair and Regeneration in ARDS: Role of PECAM1 and Wnt Signaling , 2019, Chest.

[9]  F. Aoki,et al.  Severe Acute Respiratory Syndrome-Related Coronavirus Is Inhibited by Interferon-α , 2004, The Journal of infectious diseases.

[10]  S. Lindstrom,et al.  First Case of 2019 Novel Coronavirus in the United States , 2020, The New England journal of medicine.

[11]  Z. Fayad,et al.  CT Imaging Features of 2019 Novel Coronavirus (2019-nCoV) , 2020, Radiology.

[12]  P. Chan,et al.  Experience of using convalescent plasma for severe acute respiratory syndrome among healthcare workers in a Taiwan hospital , 2005, The Journal of antimicrobial chemotherapy.

[13]  Xiaotao Lu,et al.  Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease , 2018, mBio.

[14]  Y. Guan,et al.  In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds , 2004, Journal of Clinical Virology.

[15]  The involvement of natural killer cells in the pathogenesis of severe acute respiratory syndrome. , 2004, American journal of clinical pathology.

[16]  Cheng-wei Lu,et al.  2019-nCoV transmission through the ocular surface must not be ignored , 2020, The Lancet.

[17]  V. Arumugaswami,et al.  Insights into Cross-species Evolution of Novel Human Coronavirus SARS-CoV-2 and Defining Immune Determinants for Vaccine Development , 2020, bioRxiv.

[18]  Catharine I Paules,et al.  Coronavirus Infections-More Than Just the Common Cold. , 2020, JAMA.

[19]  W. Seeger,et al.  Mesenchymal Stem Cells in Fibrotic Disease. , 2017, Cell stem cell.

[20]  Chuan Qin,et al.  From SARS to MERS, Thrusting Coronaviruses into the Spotlight , 2019, Viruses.

[21]  P. Vollmar,et al.  Transmission of 2019-nCoV Infection from an Asymptomatic Contact in Germany , 2020, The New England journal of medicine.

[22]  W. Lu,et al.  ACE2 Expression in Kidney and Testis May Cause Kidney and Testis Damage After 2019-nCoV Infection , 2020, medRxiv.

[23]  Taojiao Wang,et al.  Caution on Kidney Dysfunctions of 2019-nCoV Patients , 2020 .

[24]  Victor M Corman,et al.  Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR , 2020, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[25]  Chengyu Jiang,et al.  Anti-malaria drug chloroquine is highly effective in treating avian influenza A H5N1 virus infection in an animal model , 2012, Cell Research.

[26]  Z. Memish,et al.  Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study , 2013, The Lancet Infectious Diseases.

[27]  Samson S. Y. Wong,et al.  The management of coronavirus infections with particular reference to SARS , 2008, The Journal of antimicrobial chemotherapy.

[28]  D. Swerdlow,et al.  Clinicopathologic, Immunohistochemical, and Ultrastructural Findings of a Fatal Case of Middle East Respiratory Syndrome Coronavirus Infection in the United Arab Emirates, April 2014 , 2016, The American Journal of Pathology.

[29]  H. Doerr,et al.  Antiviral activity of glycyrrhizic acid derivatives against SARS-coronavirus. , 2005, Journal of medicinal chemistry.

[30]  Y. Leo,et al.  COVID-19 in Singapore-Current Experience: Critical Global Issues That Require Attention and Action. , 2020, JAMA.

[31]  R. Brookmeyer,et al.  Incubation periods of acute respiratory viral infections: a systematic review , 2009, The Lancet Infectious Diseases.

[32]  Jing Zhao,et al.  Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia , 2020, The New England journal of medicine.

[33]  Xin Li,et al.  The clinical pathology of severe acute respiratory syndrome (SARS): a report from China , 2003, The Journal of pathology.

[34]  Huachen Zhu,et al.  Identification of 2019-nCoV related coronaviruses in Malayan pangolins in southern China , 2020, bioRxiv.

[35]  Lisa E. Gralinski,et al.  Return of the Coronavirus: 2019-nCoV , 2020, Viruses.

[36]  Wenhui Li,et al.  A 193-Amino Acid Fragment of the SARS Coronavirus S Protein Efficiently Binds Angiotensin-converting Enzyme 2* , 2004, Journal of Biological Chemistry.

[37]  T. Kuiken,et al.  Human monoclonal antibody as prophylaxis for SARS coronavirus infection in ferrets , 2004, The Lancet.

[38]  F. Tsai,et al.  Anti-SARS coronavirus 3C-like protease effects of Isatis indigotica root and plant-derived phenolic compounds , 2005, Antiviral Research.

[39]  P. Horby,et al.  Evaluation of Convalescent Plasma for Ebola Virus Disease in Guinea. , 2016, The New England journal of medicine.

[40]  Ting Yu,et al.  Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study , 2020, The Lancet.

[41]  B. Graham,et al.  Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation , 2020, Science.

[42]  Houli Wang,et al.  The cytokine storm and factors determining the sequence and severity of organ dysfunction in multiple organ dysfunction syndrome. , 2008, The American journal of emergency medicine.

[43]  Wei Zhang,et al.  Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment. , 2020, Bioscience trends.

[44]  E. Fish,et al.  Characterization of the antiviral effects of interferon-α against a SARS-like coronoavirus infection in vitro , 2006, Cell Research.

[45]  Hannah R. Meredith,et al.  The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application , 2020, Annals of Internal Medicine.

[46]  L. Ortiz,et al.  Interleukin 1 receptor antagonist mediates the antiinflammatory and antifibrotic effect of mesenchymal stem cells during lung injury , 2007, Proceedings of the National Academy of Sciences.

[47]  Malik Peiris,et al.  Molecular Diagnosis of a Novel Coronavirus (2019-nCoV) Causing an Outbreak of Pneumonia , 2020, Clinical chemistry.

[48]  Z. Memish,et al.  The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health — The latest 2019 novel coronavirus outbreak in Wuhan, China , 2020, International Journal of Infectious Diseases.

[49]  J. Robins,et al.  Transmission Dynamics and Control of Severe Acute Respiratory Syndrome , 2003, Science.

[50]  H. Doerr,et al.  Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus , 2003, The Lancet.

[51]  A. Walls,et al.  Unexpected Receptor Functional Mimicry Elucidates Activation of Coronavirus Fusion , 2019, Cell.

[52]  Charles S Dela Cruz,et al.  Novel Wuhan (2019-nCoV) Coronavirus. , 2020, American journal of respiratory and critical care medicine.

[53]  Khamitov Ra,et al.  Antiviral activity of arbidol and its derivatives against the pathogen of severe acute respiratory syndrome in the cell cultures , 2008 .

[54]  Kwok-Hung Chan,et al.  Consistent Detection of 2019 Novel Coronavirus in Saliva , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[55]  J. Tong,et al.  Evaluation of coronavirus in tears and conjunctival secretions of patients with SARS‐CoV‐2 infection , 2020, Journal of medical virology.

[56]  A. Trounson,et al.  Human umbilical cord mesenchymal stem cells reduce fibrosis of bleomycin-induced lung injury. , 2009, The American journal of pathology.

[57]  J. Rocklöv,et al.  The reproductive number of COVID-19 is higher compared to SARS coronavirus , 2020, Journal of travel medicine.

[58]  S. Perlman,et al.  Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology , 2017, Seminars in Immunopathology.

[59]  C. Rinaldo.  Passive immunization against poliomyelitis: the Hammon gamma globulin field trials, 1951-1953. , 2005, American journal of public health.

[60]  Reduction and Functional Exhaustion of T Cells in Patients With Coronavirus Disease 2019 (COVID-19) , 2020, Frontiers in Immunology.

[61]  P. Niu,et al.  Genome Composition and Divergence of the Novel Coronavirus (2019-nCoV) Originating in China , 2020, Cell Host & Microbe.

[62]  Christian Drosten,et al.  Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC , 2013, Nature.

[63]  Mark Chappell,et al.  A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus–induced lung injury , 2005, Nature Medicine.

[64]  J. Leibowitz,et al.  The structure and functions of coronavirus genomic 3′ and 5′ ends , 2015, Virus Research.

[65]  Ton de Jong,et al.  Pegylated interferon-α protects type 1 pneumocytes against SARS coronavirus infection in macaques , 2004, Nature Medicine.

[66]  Jaap Goudsmit,et al.  Human Monoclonal Antibody Combination against SARS Coronavirus: Synergy and Coverage of Escape Mutants , 2006, PLoS medicine.

[67]  B. Murphy,et al.  An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus , 2004, Nature Medicine.

[68]  Yuqiong Yang,et al.  Therapeutic and triage strategies for 2019 novel coronavirus disease in fever clinics , 2020, The Lancet Respiratory Medicine.

[69]  E. Holmes,et al.  Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding , 2020, The Lancet.

[70]  Wu Zhong,et al.  Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro , 2020, Cell Research.

[71]  Hannah R. Meredith,et al.  The incubation period of 2019-nCoV from publicly reported confirmed cases: estimation and application , 2020 .

[72]  S. Zhang,et al.  Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series , 2020, BMJ.

[73]  Y. Guan,et al.  Coronavirus as a possible cause of severe acute respiratory syndrome , 2003, The Lancet.

[74]  M. Caligiuri,et al.  Molecular Basis for the Recognition of Herpes Simplex Virus Type 1 Infection by Human Natural Killer Cells , 2018, Front. Immunol..

[75]  Caution on Kidney Dysfunctions of COVID-19 Patients , 2020 .

[76]  Fang Li,et al.  Structure, Function, and Evolution of Coronavirus Spike Proteins. , 2016, Annual review of virology.

[77]  D. Falzarano,et al.  SARS and MERS: recent insights into emerging coronaviruses , 2016, Nature Reviews Microbiology.

[78]  Lirong Chen,et al.  Small Molecules Blocking the Entry of Severe Acute Respiratory Syndrome Coronavirus into Host Cells , 2004, Journal of Virology.

[79]  R. Baric,et al.  Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV , 2020, Nature Communications.

[80]  K. To,et al.  Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan , 2020, Emerging microbes & infections.

[81]  S. Lo,et al.  A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster , 2020, The Lancet.

[82]  Bo Diao,et al.  Reduction and Functional Exhaustion of T Cells in Patients With Coronavirus Disease 2019 (COVID-19) , 2020, Frontiers in Immunology.

[83]  Haixia Zhou,et al.  Cryo-electron microscopy structures of the SARS-CoV spike glycoprotein reveal a prerequisite conformational state for receptor binding , 2016, Cell Research.

[84]  Jia-Fu Jiang,et al.  Identifying SARS-CoV-2-related coronaviruses in Malayan pangolins , 2020, Nature.

[85]  H. Feldmann,et al.  Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection , 2020, Proceedings of the National Academy of Sciences.

[86]  J. Dennis,et al.  Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome: a preliminary study. , 2003, JAMA.

[87]  Xinhao Li,et al.  Molecular Modeling Evaluation of the Binding Effect of Ritonavir, Lopinavir and Darunavir to Severe Acute Respiratory Syndrome Coronavirus 2 Proteases , 2020, bioRxiv.

[88]  Heshui Shi,et al.  Evolution of CT Manifestations in a Patient Recovered from 2019 Novel Coronavirus (2019-nCoV) Pneumonia in Wuhan, China , 2020, Radiology.

[89]  Z. Memish,et al.  Middle East respiratory syndrome coronavirus: risk factors and determinants of primary, household, and nosocomial transmission , 2018, The Lancet Infectious Diseases.

[90]  Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody , 2020, Emerging microbes & infections.

[91]  Y. Hu,et al.  Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China , 2020, The Lancet.

[92]  Michael B Edmond,et al.  Managing SARS amidst uncertainty. , 2003, The New England journal of medicine.

[93]  Shuo Su,et al.  MERS in South Korea and China: a potential outbreak threat? , 2015, The Lancet.

[94]  M. Matthay,et al.  Mesenchymal stem cells for acute lung injury: preclinical evidence. , 2010, Critical care medicine.

[95]  V. Misra,et al.  Bats and Coronaviruses , 2019, Viruses.

[96]  L. Lanier,et al.  Direct Recognition of Cytomegalovirus by Activating and Inhibitory NK Cell Receptors , 2002, Science.

[97]  Huixia Yang,et al.  Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records , 2020, The Lancet.

[98]  J. Arribas,et al.  Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and two nucleosides for maintenance therapy of HIV , 2008, AIDS.

[99]  V. A. Maksimov,et al.  [Antiviral activity of arbidol and its derivatives against the pathogen of severe acute respiratory syndrome in the cell cultures]. , 2008, Voprosy virusologii.

[100]  G. Gao,et al.  Bat-to-human: spike features determining ‘host jump’ of coronaviruses SARS-CoV, MERS-CoV, and beyond , 2015, Trends in Microbiology.

[101]  Huji Xu,et al.  The digestive system is a potential route of 2019-nCov infection: a bioinformatics analysis based on single-cell transcriptomes , 2020, bioRxiv.

[102]  Yi Shi,et al.  Cryo-EM structures of MERS-CoV and SARS-CoV spike glycoproteins reveal the dynamic receptor binding domains , 2017, Nature Communications.

[103]  Runnan Shen,et al.  Molecular Modeling Evaluation of the Binding Abilities of Ritonavir and Lopinavir to Wuhan Pneumonia Coronavirus Proteases , 2020 .

[104]  E. Galanis,et al.  Investigation of a nosocomial outbreak of severe acute respiratory syndrome (SARS) in Toronto, Canada. , 2003, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[105]  P. Chan,et al.  Use of convalescent plasma therapy in SARS patients in Hong Kong , 2004, European Journal of Clinical Microbiology and Infectious Diseases.

[106]  Don Klinkenberg,et al.  Incubation period of 2019 novel coronavirus (2019-nCoV) infections among travellers from Wuhan, China, 20–28 January 2020 , 2020, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[107]  K. Matsushima,et al.  Minimally cultured bone marrow mesenchymal stem cells ameliorate fibrotic lung injury , 2009, European Respiratory Journal.

[108]  G. Gao,et al.  A Novel Coronavirus from Patients with Pneumonia in China, 2019 , 2020, The New England journal of medicine.

[109]  Y. Guan,et al.  Treatment with convalescent plasma for influenza A (H5N1) infection. , 2007, The New England journal of medicine.

[110]  D. Hui,et al.  Middle East respiratory syndrome , 2015, The Lancet.

[111]  Jiyuan Zhang,et al.  Pathological findings of COVID-19 associated with acute respiratory distress syndrome , 2020, The Lancet Respiratory Medicine.

[112]  Alimuddin Zumla,et al.  Coronaviruses — drug discovery and therapeutic options , 2016, Nature Reviews Drug Discovery.

[113]  J. Peiris,et al.  Prolonged disturbances of in vitro cytokine production in patients with severe acute respiratory syndrome (SARS) treated with ribavirin and steroids , 2004, Clinical and experimental immunology.

[114]  C. Romagnani,et al.  Natural killer cell specificity for viral infections , 2018, Nature Immunology.

[115]  Victor M Corman,et al.  Middle East respiratory syndrome coronavirus neutralising serum antibodies in dromedary camels: a comparative serological study , 2013, The Lancet Infectious Diseases.

[116]  Jae W. Lee,et al.  Intrapulmonary Delivery of Bone Marrow-Derived Mesenchymal Stem Cells Improves Survival and Attenuates Endotoxin-Induced Acute Lung Injury in Mice1 , 2007, The Journal of Immunology.

[117]  Ping Chen,et al.  Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission , 2020, Science China Life Sciences.

[118]  Ralph S. Baric,et al.  A decade after SARS: strategies for controlling emerging coronaviruses , 2013, Nature Reviews Microbiology.

[119]  Cheng Luo,et al.  Binding interaction of quercetin-3-β-galactoside and its synthetic derivatives with SARS-CoV 3CLpro: Structure–activity relationship studies reveal salient pharmacophore features , 2006, Bioorganic & Medicinal Chemistry.

[120]  Hansen Chen,et al.  Potential Natural Compounds for Preventing 2019-nCoV Infection , 2020 .

[121]  Y. Guan,et al.  Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings , 2004, Thorax.